💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Canakinumab

CHEMBL1201834 Phase 4 अनुमोदित Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A monoclonal antibody that blocks interleukin-1 beta, a key mediator of inflammation, used to treat rare autoinflammatory diseases such as systemic juvenile idiopathic arthritis, Still's disease, and certain periodic fever syndromes. It provides targeted immunosuppression without broadly suppressing the immune system. It is given by subcutaneous injection every few weeks to months.

चिकित्सीय क्षेत्र

HIV/एड्स अग्नाशय कैंसर अनिद्रा अस्थमा उच्च रक्तचाप एज-रिलेटेड मैक्युलर डिजनरेशन एट्रियल फ़िब्रिलेशन कोलोरेक्टल कैंसर क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) गाउट (गठिया) टाइप 2 मधुमेह दर्द प्रबंधन दीर्घकालिक दर्द नॉन-स्मॉल सेल लंग कैंसर मेलानोमा रुमेटॉइड आर्थराइटिस ल्यूकेमिया स्तन कैंसर हृदय विफलता हृदय-संवहनी रोग

क्रिया का तंत्र

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

A monoclonal antibody that blocks interleukin-1 beta, a key mediator of inflammation, used to treat rare autoinflammatory diseases such as systemic juvenile idiopathic arthritis, Still's disease, and certain periodic fever syndromes. It provides targeted immunosuppression without broadly suppressing the immune system. It is given by subcutaneous injection every few weeks to months.

Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.

Yes, Canakinumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201834. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.